About Venn

A trusted partner in the life science industry for over 25 years

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

These carefully combined services enable us to provide our customers with a complete service on all the stages of their drug development programs, from the early planning phase to final execution.

Venn Life Sciences features offices in Breda (Netherlands) and Paris (France) that offer expertise and capabilities in: CMC, Non-Clinical, Clinical Pharmacology and Development, Statistics, Study design and Methodology, Data Management, RTSM and Regulatory Affairs across a wide variety of therapeutic areas.

Our mission is to deliver high quality drug and device development services to our customers across their product development life cycle.

We play a pivotal role in the development of new products, enabling disease prevention and treatment through:

Long term partnerships

Providing comprehensive added-value services in the long-term.

Anticipating customer needs

Development and integration of new services anticipated by customer needs.

Operational Excellence

Ensuring operational excellence across our service lines.

Group companies overview

In January 2020, hVIVO merged with Open Orphan plc, a rapidly growing niche CRO pharmaceutical services company.

On 26 October 2022, Open Orphan plc changed its name to hVIVO plc to maximise its brand recognition as the world leader in human challenge trials. hVIVO is now the parent company of both Venn Life Sciences, and CRS. Venn is an integrated drug development consultancy, offering CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution (including data management and statics management. More recently, in 2025 hVIVO acquired CRS, CRS specialises in early phase clinical development, from First-in-Human and proof of concept studies. Together, the companies offer a full-service solution, from consultancy and drug development, to running phase I First-in-Human studies to human challenge model trials.

Building on decades of unrivalled experience, we provide world class expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, CL2 and CL3 specialist laboratory services and specialist drug development and clinical consultancy services.

hVIVO

CRS

hLAB

Flucamp

hVIVO is a full-service early phase Contract Research Organisation (CRO) offering end-to-end drug development services from preclinical consultancy through to Phase III clinical trials and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials.

Visit hVIVO

CRS is a leading early phase CRO with state-of-the-art research units in Germany, excelling in innovative solutions for early clinical development, from First-in-Human studies to Proof-of-Concept trials in patients.

Visit CRS

hLAB is a highly specialised infectious disease and immunology laboratory offering a suite of services to support pre-clinical and drug and vaccine discovery & development.

Through the acquisition of Cryostore™, hLAB have extended their storage offering to the biotech and pharmaceutical industries with locations in London and Cambridge. Crystore™ is a dedicated GxP storage facility for biological and clinical materials in secure temperature-controlled conditions.

Visit hLAB Visit Cryostore™